Editas Medicine receives approval for Phase 1/2 EDIT-401 trial, aiming for 2027 data
Editas Medicine received approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia to treat hyperlipidemia, with plans to report initial safety data in Q1 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed